Filing Details
- Accession Number:
- 0001209191-21-004570
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-01-20 20:20:13
- Reporting Period:
- 2021-01-19
- Accepted Time:
- 2021-01-20 20:20:13
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1377121 | Protagonist Therapeutics Inc | PTGX | () | DE |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1120477 | D Ph V Dinesh Patel | C/O Protagonist Therapeutics, Inc. 7707 Gateway Blvd., Suite 140 Newark CA 94560 | President And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2021-01-19 | 13,000 | $4.21 | 450,990 | No | 4 | M | Direct | |
Common Stock | Disposition | 2021-01-19 | 24,846 | $24.60 | 426,144 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy) | Disposition | 2021-01-19 | 13,000 | $0.00 | 13,000 | $4.21 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
165,742 | 2026-04-29 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 include: (a) the open market sale of 13,000 shares of common stock acquired pursuant to the exercise of options to purchase common stock; and (b) the open market sale of an additional 11,846 shares of common stock. Such transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 6, 2020.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.01 to $24.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- 1/48th of the shares subject to the option vested on the last day of each month following the vesting commencement date. The option became fully vested on April 25, 2020.